CALABASAS, Calif., March 15, 2006 (PRIMEZONE) -- Aspyra, Inc. (AMEX:APY), a global provider of clinical and diagnostic data management and systems for the healthcare industry, today announced that the Kon-Lin Letter, a leading subscription-based stock market advisory service, has initiated coverage of the Company in its March 2006 newsletter with an initial price target of $5.00-$6.00 per share, and a longer term target of $8.00 to $9.00.
The Kon-Lin Letter is a 40-year-old publication noted for its fundamental and technical analysis of individual stocks and market movements. Kon-Lin's research report can be accessed on Aspyra's website at www.aspyra.com.
About Aspyra, Inc.
Aspyra is a leading developer and supplier of Health Care Information Technology (HCIT) to the healthcare industry. The Company specializes in Clinical Information Systems (CIS) and Clinical Imaging Management Systems (CIMS) for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers, orthopedic environments and pharmacies. Aspyra's highly scalable enterprise-wide systems can be installed on a standalone or integrated basis and provide a single-vendor solution. For more information on Aspyra, its products and services, visit www.aspyra.com.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for Aspyra's markets and the demand for its products. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. Factors that could cause Aspyra's actual results to differ materially from these forward-looking statements include among others: whether the combined company will realize the potential benefits of the merger; the competitive environment; unexpected technical and marketing difficulties inherent in major product development efforts; the potential need for changes in our long-term strategy in response to future developments; future advances in clinical information technology and procedures, as well as potential changes in government regulations and healthcare policies; and rapid technological change in the microelectronics and software industries. The Company refers interested persons to its most recent Annual Report on Form 10-KSB and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.
The Aspyra, Inc. company logo is available at:http://www.primezone.com/newsroom/prs/?pkgid=2328